Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.69 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3818986 | 0.90 | HDAC1 (0.61) | HDAC1RAB9AHDAC6 | |
| SCHEMBL14531729 | 0.86 | HDAC1 (0.61) | HDAC1RAB9APKMTP53LMNA | |
| SCHEMBL238713 | 0.78 | L3MBTL1 (0.57) | RAB9A | |
| SCHEMBL14532051 | 0.76 | HDAC1 (0.54) | HDAC1RAB9A | |
| SCHEMBL3809405 | 0.75 | RAB9A (0.65) | HDAC1RAB9APKMTP53 | |
| SCHEMBL3813891 | 0.73 | RAB9A (0.61) | HDAC1RAB9APKMTP53 | |
| SCHEMBL10184438 | 0.69 | HDAC6 (0.56) | HDAC6 | |
| SCHEMBL1761713 | 0.69 | NPC1 (0.47) | RAB9A | |
| SCHEMBL4608538 | 0.69 | KMT2A (0.54) | HDAC1HDAC6 | |
| SCHEMBL18361662 | 0.68 | RAB9A (0.77) | HDAC1RAB9APKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | claimed |
| EP-1948190-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | claimed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-14 | — | — | US | disclosed |
| EP-1948190-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007051810-A2 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | TRANSTECH PHARMA (US) | 2007-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124598-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD11B2, HSD3B1 | HDAC1 113/4885RAB9A 3233/4885PKM 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.